

MD Anderson at SSO

MDAnderson.org/SSO

MD Anderson
Cancer Center

Making Cancer History®

Wednesday, March 26		As of March 20
7:15 a.m.-3:15 p.m.	Pre-Course: Hands-On Robotics in Gastrectomy, Esophagectomy, Pancreas, Liver (Non-CME)	CAMLS Lab
8:40-8:50 a.m.	Gastrectomy and Esophagectomy: How I Do It: Gastrectomy and D2 Lymphadenectomy	Naruhiko Ikoma, M.D.
10:20-10:30 a.m.	Liver: How I Do It—Right Hepatectomy	Hop Tran Cao, M.D.
10:30 a.m.-3:15 p.m.	Hands-On Lab & Hands-On Procedure	Hop Tran Cao, M.D. Naruhiko Ikoma, M.D.
9:00 a.m.-4:00 p.m.	Pre-Course: Surgical Clinical Trials Primer—Designing Your Study (Non-CME)	Room 120-121
9:45-10:05 a.m.	Designing Your Clinical Trial: Defining Your Trial’s Clinical Endpoints	Christina Roland, M.D.
Thursday, March 27		
10:00-10:20 a.m.	Top Poster Presentations	HUB Poster Park
Easel #7	P69. Leveraging community-based participatory feedback to identify barriers in research participation for underrepresented populations with rare cancer	Sophia Williams-Perez, M.D.
10:30 a.m.-12:00 p.m.	Symposium: Biomarker Based Treatment Stratification for Peritoneal Surface Malignancies	Ballroom A
10:47-11:02 a.m.	RAS/RAF Status and Patient Stratification	Beth Helmink, M.D., Ph.D.
1:50-3:20 p.m.	Symposium: Impact of Contemporary High-Impact Trials on Surgical Management of Patients with Sarcoma	Ballroom A
1:53-2:18 p.m.	The Impact of SU2C-SARC-032 on the Multi-Disciplinary Management of Patients with High-Risk Soft Tissue Sarcoma	Emily Keung, M.D.
4:00-5:00 p.m.	Great Debate: Zeal to Operate vs Ignoring the Evidence	Ballroom A
4:00-4:02 p.m.	Introduction: Diverting Ostomy after Neoadjuvant Therapy During Sphincter Preservation Surgery for Rectal Cancer: Standard of Care	Y. Nancy You, M.D.
4:30-4:32 p.m.	Introduction: Patients with Resectable Bilobar Colorectal Cancer Liver Metastasis: Upfront Surgery vs Molecular-Guided Neoadjuvant Chemotherapy	
4:41-4:50 p.m.	Upfront Surgery	Brian Bednarski, M.D.
4:52-4:54 p.m.	Rebuttal: Upfront Surgery	
4:00-5:00 p.m.	Resident/Fellow Programming: Poster Presentations	Room 124-125
4:02-4:08 p.m.	P143. Real-world outcomes of patients with clinically node positive melanoma undergoing neoadjuvant immunotherapy and nodal dissection	Joshua Herb, M.D.
4:20-4:26 p.m.	P138. Nodal imaging concordance with pathologic findings after neoadjuvant immunotherapy in patients with stage III melanoma	
Friday, March 28		
8:00-9:30 a.m.	Best Papers I	Ballroom BC
8:02-8:08 a.m.	51. Eliminating breast surgery for invasive cancer after neoadjuvant systemic therapy: 5-year outcomes on an inaugural multicenter phase II clinical trial	Henry Kuerer, M.D., Ph.D.
9:40-10:00 a.m.	Continuing the Conversation: Meet the Physician Scientists	Breast/Endocrine HUB Zone

	Speaker	Emily Keung, M.D.
1:00-2:30 p.m.	Best Papers II	Ballroom BC
2:04-2:10 p.m.	89. Predicting pathologic N2 breast cancer in pre- and post-menopausal patients with positive sentinel lymph nodes	Kerollos Wanis, M.D., Ph.D.
1:00-2:30 p.m.	Symposium: Updates in Therapeutics	Ballroom D
1:00-1:15 p.m.	Role of Checkpoint Inhibition in Retroperitoneal Sarcoma	Christina Roland, M.D.
1:00-2:30 p.m.	Abstract Presentations: HPB II	Room 122-123
	Moderator	Rebecca Snyder, M.D.
2:35-3:35 p.m.	Great Debate: Less Is More, Or Is It? Right-Sizing of Thyroid Cancer Care	Ballroom D
3:05-3:20 p.m.	Multimodality Management of Treatment Resistant or Recurrent Advanced Thyroid Cancer	Sarah Fisher, M.D.
4:15-5:15 p.m.	Abstract Presentations: Quality/Disparities	Room 122-123
	Moderator	Matthew Katz, M.D.
Saturday, March 29		
8:30-10:00 a.m.	Symposium: Advances in Endocrine Surgery	Ballroom D
9:30-9:45 a.m.	Advances in Management of Parathyroid Disease	Nancy Perrier, M.D.
8:30-10:00 a.m.	Abstract Presentations: Breast II	Room 122-123
9:40-9:46 a.m.	127. Sentinel lymph node involvement in triple negative breast cancer: Predictive factors and implications for axillary surgery decision-making	Ashley Cairns
10:30 a.m.-12:00 p.m.	Great Debate: Debates and Controversies in Soft Tissue Oncology	Ballroom D
11:30-11:42 a.m.	Is Less More? Ultra-Hypofractionated Radiation for Soft Tissue Sarcoma Should Be the New Standard of Care	Christina Roland, M.D.
11:47-11:52 a.m.	Negative: Standard and Moderately Fractionated Radiation Should Remain Standard of Care for Soft Tissue Sarcoma	
11:30-11:42 a.m.	Negative: Rebuttal	
10:30 a.m.-12:00 p.m.	Symposium: Safe Dissemination of New Technologies or Treatments in Practice	Room 122-123
	Chair	Matthew Katz, M.D.
10:30-11:00 a.m.	How to Safely Learn and Incorporate New Techniques: The Practicing Surgeon and Program/Department Leader	Hop Tran Cao, M.D.